349 related articles for article (PubMed ID: 25051202)
1. BRAF V600 mutations and pathological features in Japanese melanoma patients.
Yamazaki N; Tanaka R; Tsutsumida A; Namikawa K; Eguchi H; Omata W; Oashi K; Ogawa T; Hayashi A; Nakamura N; Tsuta K
Melanoma Res; 2015 Feb; 25(1):9-14. PubMed ID: 25051202
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
[TBL] [Abstract][Full Text] [Related]
3. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.
Lang J; MacKie RM
J Invest Dermatol; 2005 Sep; 125(3):575-9. PubMed ID: 16117801
[TBL] [Abstract][Full Text] [Related]
6. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas.
Lade-Keller J; Rømer KM; Guldberg P; Riber-Hansen R; Hansen LL; Steiniche T; Hager H; Kristensen LS
J Mol Diagn; 2013 Jan; 15(1):70-80. PubMed ID: 23159593
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting.
Scolyer RA; Atkinson V; Gyorki DE; Lambie D; O'Toole S; Saw RPM; Amanuel B; Angel CM; Button-Sloan AE; Carlino MS; Ch'ng S; Colebatch AJ; Daneshvar D; Pires da Silva I; Dawson T; Ferguson PM; Foster-Smith E; Fox SB; Gill AJ; Gupta R; Henderson MA; Hong AM; Howle JR; Jackett LA; James C; Lee CS; Lochhead A; Loh D; McArthur GA; McLean CA; Menzies AM; Nieweg OE; O'Brien BH; Pennington TE; Potter AJ; Prakash S; Rawson RV; Read RL; Rtshiladze MA; Shannon KF; Smithers BM; Spillane AJ; Stretch JR; Thompson JF; Tucker P; Varey AHR; Vilain RE; Wood BA; Long GV
Pathology; 2022 Feb; 54(1):6-19. PubMed ID: 34937664
[TBL] [Abstract][Full Text] [Related]
9. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays.
Qu K; Pan Q; Zhang X; Rodriguez L; Zhang K; Li H; Ho A; Sanders H; Sferruzza A; Cheng SM; Nguyen D; Jones D; Waldman F
J Mol Diagn; 2013 Nov; 15(6):790-5. PubMed ID: 23994118
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
11. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
12. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
Kim A; Cohen MS
Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
[TBL] [Abstract][Full Text] [Related]
13. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
14. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma.
Busser B; Leccia MT; Gras-Combe G; Bricault I; Templier I; Claeys A; Richard MJ; de Fraipont F; Charles J
JAMA Dermatol; 2013 Dec; 149(12):1403-6. PubMed ID: 24108467
[TBL] [Abstract][Full Text] [Related]
16. BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis.
Maxwell R; Garzon-Muvdi T; Lipson EJ; Sharfman WH; Bettegowda C; Redmond KJ; Kleinberg LR; Ye X; Lim M
Int J Cancer; 2017 Jun; 140(12):2716-2727. PubMed ID: 27342756
[TBL] [Abstract][Full Text] [Related]
17. Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.
Lopez-Rios F; Angulo B; Gomez B; Mair D; Martinez R; Conde E; Shieh F; Vaks J; Langland R; Lawrence HJ; de Castro DG
PLoS One; 2013; 8(1):e53733. PubMed ID: 23326492
[TBL] [Abstract][Full Text] [Related]
18. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
20. Multi-center evaluation of the novel fully-automated PCR-based Idylla™ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma.
Melchior L; Grauslund M; Bellosillo B; Montagut C; Torres E; Moragón E; Micalessi I; Frans J; Noten V; Bourgain C; Vriesema R; van der Geize R; Cokelaere K; Vercooren N; Crul K; Rüdiger T; Buchmüller D; Reijans M; Jans C
Exp Mol Pathol; 2015 Dec; 99(3):485-91. PubMed ID: 26407762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]